
Opinion|Videos|November 30, 2023
Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.
Advertisement
Episodes in this series

Advertisement
Related to this article

Colleen Carvalho, chief mission officer at Bay Area Cancer Connections, explains the emotional and practical needs that often go unaddressed after a diagnosis.

Claudine Joseph, board president of Bay Area Cancer Connections, shares her mother’s breast cancer experience and why peer support matters for all patients.

Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.

Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.

Dr. Elham Vosoughi, a breast medical oncologist at UCSF, discusses new breast cancer treatments, clinical trials and why genetic testing matters for families.

Births to cancer survivors in U.S. hospitals rose from 2016 to 2023, and most went to full term, but survivors had more serious delivery complications than people who never had cancer, a large study found.

Jessica Tovar, owner of Ink Esthetics, explained how paramedical tattooing can help restore the appearance of the areola and support patients after breast cancer surgery.
Advertisement
Advertisement

